Hypercalcemia following discontinuation of denosumab therapy: A systematic review
Denosumab is a monoclonal antibody that has been approved to treat osteoporosis, skeletal metastasis, and giant cell tumor of bone in skeletally mature patients. Due to its potential adverse effects on normal bone growth, its use has not yet been approved in skeletally immature patients; however, th...
Guardado en:
Autores principales: | Keisuke Horiuchi, Eisuke Kobayashi, Tsukasa Mizuno, Michiro Susa, Kazuhiro Chiba |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fd67b69514304e609ca96a677fff2bf5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Slow speed resistance exercise training in children with polyarticular juvenile idiopathic arthritis
por: Sule SD, et al.
Publicado: (2019) -
Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas KM, et al.
Publicado: (2014) -
Persistent hypercalcemia with similar familial Hypocalciuric hypercalcemia features: a case report and literature review
por: Maryam Zahedi, et al.
Publicado: (2021) -
No increased risk of Alzheimer’s disease among people with immune-mediated inflammatory diseases: findings from a longitudinal cohort study of U.S. older adults
por: Michael J. Booth, et al.
Publicado: (2021) -
Metabolic syndrome in adults with a history of juvenile arthritis
por: Sule S, et al.
Publicado: (2018)